AVODART® Alopecia Post-marketing Surveillance (PMS)
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information
In the register
The register attaches this trial to Dutasteride (Avodart / Zagallo) (GSK), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- No phase declared
- Sponsor
- GlaxoSmithKline
- Participants (registry)
- 712
- Start
- April 2010
- Primary completion
- December 2012
- Study completion
- December 2012
- Last registry update
- June 2018
- Countries
- South Korea
Conditions studied: Alopecia
Interventions: Dutasteride
Other trials of Dutasteride (Avodart / Zagallo)
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.